glutathione iv therapy inspirada Glutathione IV - Oasis Health

Lander ES, Linton LM, Birren B et al (2001) International Human Genome Sequencing Consortium

We agree with the applicant that the TOPS TM System meets the cost criterion and are therefore proposing to approve the TOPS TM System for new technology add-on payments for FY 2024, subject to the technology receiving FDA marketing authorization as a Breakthrough Device for the indication corresponding to the Breakthrough Device designation by July 1, 2023

However, controlled human trials have not been published, making evidence quality substantially lower than for Semax or Selank

doi:10.1007/s00441-019-03016-8 Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH